Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Emend Granted Broad Coverage Under Medicare Part B

This article was originally published in The Pink Sheet Daily

Executive Summary

The oral anti-emetic will be covered by Part B for first-line use in combination with dexamethasone and a 5-HT3 antagonist in patients receiving any of nine highly emetogenic chemotherapy agents under a final coverage decision memo. CMS loosens conditions for reimbursement in response to comments.

You may also be interested in...



CMS Reviewing Aprepitant NCD To Add Use With Moderately Emetogenic Chemo

The current Medicare Part B national coverage determination says use of the anti-nausea drug with highly emetogenic anti-cancer chemotherapy is reasonable and necessary; the National Comprehensive Cancer Network asks CMS to update the NCD based on evidence supporting use with moderately emetogenic agents.

Merck's Emend To Be Covered Under Part B In Draft CMS Coverage Decision

The anti-emetic would be covered by Medicare Part B when used in combination with a 5-HT3 antagonist and dexamethasone in patients refractory to standard treatments, CMS says. Other uses of Emend would be covered under Part D beginning in 2006.

Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal

A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel